ArticleFrontiers in endocrinology2026
Distinctive features of cancer-associated fibroblasts expressing CD105, a novel biomarker for bone metastasis, in early-stage invasive ductal breast cancer.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Cancer-associated fibroblasts (CAFs) are highly heterogeneous and critically influence breast cancer progression, yet functionally relevant stromal subpopulations remain poorly defined. This study investigates whether CD105 expression distinguishes fibroblast subsets with distinct mesenchymal stem-like properties and tumor-modulating functions within early-stage breast cancer. Methods: CD105(+)/CD34(-) and CD105(-)/CD34(-) fibroblast subpopulations were isolated from primary luminal breast tumors and analyzed for phenotypic, molecular, and functional characteristics, as well as for their effects on breast cancer cell behavior using Results: Both fibroblast subpopulations displayed mesenchymal stem/stromal cell (MSC) characteristics; however, CD105(+)/CD34(-) fibroblasts displayed a more pronounced MSC-like phenotype, with enhanced proliferative capacity, altered oxidative status, and a distinct gene expression and secretory profile. CM from CD105(+)/CD34(-) fibroblasts more strongly promoted migration and proliferation and increased the expression of genes associated with stemness, osteogenic differentiation, bone mineralization, and osteoclastogenesis in luminal and triple-negative human breast cancer cell lines, compared with CM from CD105(-)/CD34(-) fibroblasts. Conclusion: These findings identify CD105 as a potential functional discriminator of breast CAF subpopulations and suggest that CD105(+) fibroblasts may preferentially support tumor progression and the acquisition of bone-related traits. This work provides new insight into CAF heterogeneity and its potential relevance for metastatic progression, and may also guide future therapeutic strategies and research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.